Molecular approaches in pediatric oncology

Annual Review of Medicine

Volumn 57, Issue , 2006, Pages 83-97

  Khanna, Chand ^a   Helman, Lee J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biology; Cancer; Diagnosis; Metastasis; Therapy

Indexed keywords

CANCER DIAGNOSIS; CANCER PATIENT; CANCER RESEARCH; CANCER STAGING; CHILDHOOD CANCER; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

CHILD; GENETIC TECHNIQUES; HUMANS; NEOPLASMS;

EID: 32944471230     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.57.121304.131247     Document Type: Review

References (74)

1. Pearson HA. 2002. History of pediatric hematology oncology. Pediatr. Res. 52:979-92
2. Poplack DG. 2002. Principles and practice of pediatric oncology. In Principles and Practice of Pediatric Oncology, ed. PA Pizzo, DG Poplack. Philadelphia: Lippincott Williams & Wilkins
3. Uren A, Toretsky JA. 2005. Pediatric malignancies provide unique cancer therapy targets. Curr. Opin. Pediatr. 17:14-19
4. Vassal G. 2005. Has chemotherapy reached its limits in pediatric cancers? Eur. J. Cancer 41:564-75
5. Bronchud MH. 2004. Principles of Molecular Oncology. Totowa, NJ: Humana, xxi, 709 pp.
6. Tycko B. 2003. Genetic and epigenetic mosaicism in cancer precursor tissues. Ann. NY Acad. Sci. 983:43-54
7. Schedin P, Elias A. 2004. Multistep tumorigenesis and the microenvironment. Breast Cancer Res. 6:93-101
8. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70
9. Pantel K, Brakenhoff RH. 2004. Dissecting the metastatic cascade. Nat. Rev. Cancer 4:448-56
10. Goldsby RE, Carroll WL. 1998. The molecular biology of pediatric lymphomas. J. Pediatr. Hematol. Oncol. 20:282-96
11. Devita VT, Hellman S, Rosenberg SA. 2001. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins
12. Tannock I, Hill RP. 1998. The Basic Science of Oncology. New York: McGraw-Hill Health Prof. Div. xii, 539 pp.
13. Knudson AG Jr, Meadows AT. 1976. Developmental genetics of neuroblastoma. J. Natl. Cancer Inst. 57:675-82
14. Malkin D. 2001. The role of p53 in human cancer. J. Neurooncol. 51:231-43
15. Birch JM, Hartley AL, Blair V, et al. 1990. Identification of factors associated with high breast cancer risk in the mothers of children with soft tissue sarcoma. J. Clin. Oncol. 8:583-90
16. Pollak MN, Schernhammer ES, Hankinson SE. 2004. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4:505-18
17. Minniti CP, Tsokos M, Newton WA Jr, et al. 1994. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am. J. Clin. Pathol. 101:198-203
18. Zhan S, Shapiro DN, Helman LJ. 1994. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J. Clin. Invest. 94:445-48
19. Vermeulen K, Van Bockstaele DR, Berneman ZN. 2003. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131-49
20. Classon M, Harlow E. 2002. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2:910-17
21. Gerl R, Vaux DL. 2005. Apoptosis in the development and treatment of cancer. Carcinogenesis 26:263-70
22. Schulze-Bergkamen H, Krammer PH. 2004. Apoptosis in cancer-implications for therapy. Semin. Oncol. 31:90-119
23. Herbst RS, Frankel SR. 2004. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin. Cancer Res. 10:4245s-48s
24. Greider CW. 1998. Telomerase activity, cell proliferation, and cancer. Proc. Natl. Acad. Sci. USA 95:90-92
25. Ahmed A, Tollefsbol TO. 2003. Telomerase, telomerase inhibition, and cancer. J. Anti Aging Med. 6:315-25
26. Sanders RP, Drissi R, Billups CA, et al. 2004. Telomerase expression predicts unfavorable outcome in osteosarcoma. J. Clin. Oncol. 22:3790-97
27. Ulaner GA, Hoffman AR, Otero J, et al. 2004. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 41:155-62
28. Fidler IJ. 2003. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3:453-58
29. Khanna C, Hunter K. 2004. Modeling metastasis in vivo. Carcinogenesis 26:513-23
30. Ramaswamy S, Ross KN, Lander ES, et al. 2003. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:49-54
31. Clark EA, Golub TR, Lander ES, et al. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-35
32. Khanna C, Khan J, Nguyen P, et al. 2001. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 61:3750-59
33. Shevde LA, Welch DR. 2003. Metastasis suppressor pathways-an evolving paradigm. Cancer Lett. 198:1-20
34. Steeg PS. 2004. Perspectives on classic article: metastasis suppressor genes. J. Natl. Cancer Inst. 96:E4
35. Khanna C, Wan X, Bose S, et al. 2004. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10:182-86
36. Yu Y, Khan J, Khanna C, et al. 2004. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat. Med. 10:175-81
37. Wan X, Mendoza A, Khanna C, et al. 2005. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 65:2406-11
38. Patan S. 2004. Vasculogenesis and angiogenesis. Cancer Treat. Res. 117:3-32
39. Ellis LM, Liu W, Ahmad SA, et al. 2001. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin. Oncol. 28:94-104
40. Schneider NR. 1993. Cytogenetic evaluation of childhood neoplasms. Arch. Pathol. Lab. Med. 117:1220-24
41. Rowland JM. 2002. Molecular genetic diagnosis of pediatric cancer: current and emerging methods. Pediatr. Clin. North Am. 49:1415-35
42. Dagher R, Pham TA, Sorbara L, et al. 2001. Molecular confirmation of Ewing sarcoma. J. Pediatr. Hematol. Oncol. 23:221-24
43. Helman LJ, Meltzer P. 2003. Mechanisms of sarcoma development. Nat. Rev. Cancer 3:685-94
44. Mackall C, Berzofsky J, Helman LJ. 2000. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin. Orthop. Relat. Res. 373:25-31
45. Mackall CL, Meltzer PS, Helman LJ. 2002. Focus on sarcomas. Cancer Cell 2:175-78
46. Khan J, Simon R, Bittner M, et al. 1998. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 58:5009-13
47. Tsutsumi S, Taketani T, Nishimura K, et al. 2003. Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. Cancer Res. 63:4882-87
48. Yagi T, Morimoto A, Eguchi M, et al. 2003. Identification of a gene expression signature associated with pediatric AML prognosis. Blood 102:1849-56
49. Wei JS, Greer BT, Westermann F, et al. 2004. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 64:6883-91
50. Khan AS. 2004. Genomics and microarray for detection and diagnostics. Acta Microbiol. Immunol. Hung. 51:463-67
51. Kerst G, Kreyenberg H, Roth C, et al. 2005. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br. J. Haematol. 128:774-82
52. Athale UH, Shurtleff SA, Jenkins JJ, et al. 2001. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J. Pediatr. Hematol. Oncol. 23:99-104
53. Izraeli S, Waldman D. 2004. Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges. Acta Haematol. 112:34-39
54. Jaffer FA, Weissleder R. 2005. Molecular imaging in the clinical arena. JAMA 293:855-62
55. Greer BT, Khan J. 2004. Diagnostic classification of cancer using DNA microarrays and artificial intelligence. Ann. NY Acad. Sci. 1020:49-66
56. Hanash S. 2004. Integrated global profiling of cancer. Nat. Rev. Cancer 4:638-44
57. Yengi LG. 2005. Systems biology in drug safety and metabolism: integration of microarray, real-time PCR and enzyme approaches. Pharmacogenomics 6:185-92
58. Ferrando AA, Look AT. 2004. DNA microarrays in the diagnosis and management of acute lymphoblastic leukemia. Int. J. Hematol. 80:395-400
59. Khan J, Wei JS, Ringner M, et al. 2001. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med. 7:673-79
60. Ohira M, Oba S, Nakamura Y, et al. 2005. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7:337-50
61. Nishizuka S, Charboneau L, Young L, et al. 2003. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. USA 100:14229-34
62. Sawyers CL. 2001. Cancer treatment in the STI571 era: What will change? J. Clin. Oncol. 19:13S-16S
63. Albanell J, Gascon P. 2005. Small molecules with EGFR-TK inhibitor activity. Curr. Drug Targets 6:259-74
64. Druker BJ. 2003. Chronic myeloid leukemia in the imatinib era. Semin. Hematol. 40:1-3
65. Tuveson DA, Willis NA, Jacks T, et al. 2001. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20:5054-58
66. Sawyers CL. 2002. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J. Clin. Oncol. 20:3568-69
67. Eisenberg BL, Judson I. 2004. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann. Surg. Oncol. 11:465-75
68. Sawyers C. 2004. Targeted cancer therapy. Nature 432:294-97
69. Foulstone E, Prince S, Zaccheo O, et al. 2005. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J. Pathol. 205:145-53
70. Mansky PJ, Liewehr DJ, Steinberg SM, et al. 2002. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J. Pediatr. Hematol. Oncol. 24:440-46
71. Khanna C, Prehn J, Hayden D, et al. 2002. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin. Cancer Res. 8:2406-12
72. Sachdev D, Li SL, Kartell JS, et al. 2003. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 63:627-35
73. Meric-Bernstam F, Mills GB. 2004. Mammalian target of rapamycin. Semin. Oncol. 31:10-17
74. Dancey JE. 2005. Inhibitors of the mammalian target of rapamycin. Expert Opin. Investig. Drugs 14:313-28